

2021 台灣腫瘤消融醫學會(TATA)年會及亞洲腫瘤消融醫學講座(ACTA Lecture)

08:20~8:55	報到		
08:55~9:00	Opening Remark		理事長
Session 1: ACTA lecture 亞洲腫瘤消融醫學會講座			
09:00~09:30	Liver tumor ablation: The State of Art in Japan	Shuichiro Shiina	盧勝男 林錫銘 黃凱文
09:30~10:00	Liver tumor ablation: The State of Art in Korea	Hyunchul Rhim	
10:00~10:30	Palliative ablation, top ten tips	Uei Pua	
10:30~10:50	Coffee Break		
Session 2: Optimization of the outcomes after ablation therapy			
10:50~11:10	Combination of ablation and systemic therapy for the management of liver cancer	李懿宸	黃振義 黃怡翔 陳冠仰
11:10~11:30	The role of chemoprevention and antivirals in ablation therapy of liver cancer	陳柏岳	
11:30~11:50	Predictive factors of outcomes after ablation of hepatocellular carcinoma	李騰裕	
11:50~11:55	Discussion		
Luncheon symposium			
12:05~12:35	Thyroid: Paradigm shift from Surgery to Non-surgical treatment	Jung Hwan Baek	
12:35~12:55	DNA methylation Profile with diagnostic and prognostic potential in HCC treated by RFA	蕭智陽	
12:55~13:15	To prolong survival by combination of sorafenib and <i>Graptopetalum paraguayense</i> extraction for HCC after local ablation	黃凱文	
13:15~13:20	Discussion		
Session 3: Ablation therapy for challenging conditions			
13:30~13:50	Ablation therapy for intermediate stage HCC	洪肇宏	林成俊 牟聯瑞 徐士哲
13:50~14:10	Ablation of liver tumors in difficult locations	陳威廷	
14:10~14:30	Application of contrast ultrasonography in tumor ablation	王勝永	
14:30~14:50	Gd-EOB-DTPA-enhances MRI: applications of imaging diagnosis & interventional procedures.	柳建安	
14:50~14:55	Discussion		
14:55~15:15	Coffee Break		
Session 4: New boundary of local ablation			
15:15~15:35	The initiation of Taiwan guideline for thyroid RFA	林偉哲	沈書慧 梁博欽 莊伯恒
15:35~15:55	Cryoablation for lung cancer	簡寧	
15:55~16:15	Cryoablation for liver cancer	鄭斌男	
16:15~16:20	Discussion		
16:20~16:50	General Assembly 會員大會		
16:50~16:55	Closing Remark		理事長